References
- National Multiple Sclerosis SocietyMS prevalence Available from: http://www.nationalmssociety.org/About-the-Society/MS-PrevalenceAccessed April 28, 2015
- BethouxFBennettSEvaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?Int J MS Care201113141424453700
- AscheCVSingerMEJhaveriMAll-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United StatesJ Manag Care Pharm201016970371221067256
- AdelmanGRaneSGVillaKFThe cost of multiple sclerosis in the United States. A systematic review of the literatureJ Med Econ201316563964723425293
- ZwibelHLContribution of impaired mobility and general symptoms to the burden of multiple sclerosisAdv Ther200926121043105720082242
- HobartJLampingDFitzpatrickRThe multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measureBrain2001124Pt 596297311335698
- HeesenCBöhmJReichCPatient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuableMult Scler200814798899118505775
- PaltamaaJSarasojaTLeskinenEMeasures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosisArch Phys Med Rehabil200788121649165718047881
- PatwardhanMBMatcherDBSamsaGPCost of multiple sclerosis by level of disability: a review of literatureMult Scler200511223223915794399
- MiravalleAAGuidelines and best practices for appropriate use of dalfampridine in managed care populationsAm J Manag Care201117Suppl 5S154S16021761954
- GoodmanADBrownTRKruppLSustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialLancet2009373966573273819249634
- GoodmanADBrownTREdwardsKRA phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnn Neurol201068449450220976768
- Ampyra® (dalfampridine) extended release (ER) tablets [prescribing information]Ardsley, NYAcorda Therapeutics, Inc2014
- GoodmanADBrownTRSchapiroRTA pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosisInt J MS Care201416315316025337058
- JaraMAquilinaTAupperlePSafety profile of dalfampridine extended release in multiple sclerosis: 5-year post-marketing experience in the United StatesPoster presented at: ECTRIMSOctober 9, 2015Barcelona, Spain
- QuanHSundararajanVHalfonPCoding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative dataMed Care200543111130113916224307
- PetersonAMNauDPCramerJAA checklist for medication compliance and persistence studies using retrospective databasesValue Health201510131217261111
- RosenbaumPRRubinDBThe central role of the propensity score in observational studies for causal effectsBiometrika19837014155
- D’AgostinoRBTutorial on biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStat Med19981719226522819802183
- KurthTWalkerAMGlynnRJResults of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effectAm J Epidemiol2006163326227016371515
- AustinPCAn introduction to propensity score methods for reducing the effects of confounding in observational studiesMultivariate Behav Res201146339942421818162
- LeeALiuYGleissnerETreatment patterns and costs among patients with multiple sclerosis treated with prolonged-release fampridine in GermanyPoster presented at: ECTRIMSOctober 9, 2015Barcelona, Spain
- Milliman Research ReportMilliman Specialty Medical Drug 2010 Commercial Benchmark Study; November 26, 2012Brookfield, WIMilliman Research Report Available from: http://us.milliman.com/uploadedFiles/insight/Research/health-rr/pdfs/specialty-medical-drug-benchmark-study.pdfAccessed November 2, 2015